Treatment of advanced heart failure in adults with congenital heart disease: a narrative review and clinical cases.

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-22-230/coif). The series “Current Management Aspects in Adult Congenital Heart Disease (ACHD): Part V” was commissioned by the editorial office without any funding or sponsorship. YVK, HK and KN served as the unpaid Guest Editors of the series. HK has received honoraria for lectures and/or consultancy from Actelion, Bristol Myers Squibb, Janssen. CS receives research funding from the German Foundation for Heart Research and the Dr. Rolf Schwiete Stiftung. Further, he received speaker fees from AstraZeneca and Johnson & Johnson outside the submitted work. EZ reports speaker fees received from AstraZeneca outside the submitted work. CM reports research funding from the German Center for Cardiovascular Research (DZHK) within the Promotion of women scientist program, the Deutsche Stiftung fuer Herzforschung and the Dr. Rolf Schwiete Stiftung, and speaker fees from AstraZeneca, Novartis, Heinen&Loewenstein, Boehringer Ingelheim/Lilly, Bayer, Pfizer, Sanofi, Aventis, Apontis, Abbott outside of this study. SB reports grants and personal fees from Abbott Diagnostics, Bayer, Thermo Fisher, grants from SIEMENS, Singulex, personal fees from Abott, Astra Zeneca, AMGEN, Medtronic, Pfizer, Roche, Novartis, Siemens Diagnostics, outside the submitted work. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). HR is a consultant to Medtronic Inc. and received speaker- and travel honoraria from Abiomed Inc. and Edwards Inc. The authors have no other conflicts of interest to declare."

"Funding: None."